key: cord-0808585-ipv0htpe
authors: Ong, Kien Chai; Wong, Kum Thong
title: Henipavirus Encephalitis: Recent Developments and Advances
date: 2015-08-15
journal: Brain Pathol
DOI: 10.1111/bpa.12278
sha: 048e376dcc509f4ec4ede433c22877b4c98fc4af
doc_id: 808585
cord_uid: ipv0htpe

The genus H enipavirus within the family Paramyxoviridae includes the Hendra virus (HeV) and Nipah virus (NiV) which were discovered in the 1990s in Australia and Malaysia, respectively, after emerging to cause severe and often fatal outbreaks in humans and animals. While HeV is confined to Australia, more recent NiV outbreaks have been reported in Bangladesh, India and the Philippines. The clinical manifestations of both henipaviruses in humans appear similar, with a predominance of an acute encephalitic syndrome. Likewise, the pathological features are similar and characterized by disseminated, multi‐organ vasculopathy comprising endothelial infection/ulceration, vasculitis, vasculitis‐induced thrombosis/occlusion, parenchymal ischemia/microinfarction, and parenchymal cell infection in the central nervous system (CNS), lung, kidney and other major organs. This unique dual pathogenetic mechanism of vasculitis‐induced microinfarction and neuronal infection causes severe tissue damage in the CNS. Both viruses can also cause relapsing encephalitis months and years after the acute infection. Many animal models studied to date have largely confirmed the pathology of henipavirus infection, and provided the means to test new therapeutic agents and vaccines. As the bat is the natural host of henipaviruses and has worldwide distribution, spillover events into human populations are expected to occur in the future.

The Henipavirus genus in the subfamily Paramxyxovirinae (family Paramyxoviridae) that also includes the well-known measles virus (genus: Morbillivirus) was originally created for two pathogenic viruses, Hendra and Nipah (123) . Since then, nonpathogenic Cedar virus has also been included into Henipavirus (71) . More recently, many newly discovered African henipaviruses and a pathogenic henipavirus from the Philippines have been reported, all of which have not been isolated or fully characterized (14, 27). Hendra virus (HeV) and Nipah virus (NiV) are enveloped, pleomorphic virions with diameters averaging about 500 nm, but may range from about 40 to 1900 nm in length (38, 55) . Each virion contains a tangle of nucleocapsids with a herringbone structure typical of paramyxoviruses. As negative-sense, single-stranded RNA viruses, they have unusually large genomes of more than 18 000 nucleotides, comprising six genes encoding for the nucleocapsid, phosphoprotein, matrix protein, fusion glycoprotein (F), attachment glycoprotein (G) and the large polymerase ( Figure 1) .The viral G protein attaches to the host cell ephrin B2 and/or B3 receptor, and activates the F protein to initiate viral envelop and host membrane fusion and viral entry (4, 82, 91) .

Various aspects of HeV and NiV infections, including pathology and pathogenesis, have been reviewed previously, either individually or as henipaviruses (69, 116, 129, 130, 133, 135, 137) . The purpose of this review is to revisit what is currently known and to describe recent developments and advances of emerging henipaviruses as deadly zoonotic infections with human outbreaks continue to be reported in Bangladesh and the Philippines (14, 98) .

HeV was first isolated in 1994, five years before NiV, after an outbreak in horses and two humans in Australia, hence its original name, Equine Morbillivirus (81, 109) . To date, numerous outbreaks in horses and a total of seven human infections with four fatalities have been reported (47, 69, 85, 92) . So far, no HeV cases have been reported outside Australia.

NiV was first isolated in 1999 after outbreaks in pigs and humans in Malaysia and Singapore from 1998 to 1999 (12, 19). Although not precisely known, the number of infected pigs must have been at least in the hundreds. It was estimated that there were more than 350 human cases, both asymptomatic and symptomatic (135) , including at least 265 cases of acute NiV encephalitis with 105 fatalities (88, 89) . From 2001 onwards, several recurrent outbreaks of NiV in Bangladesh and an outbreak in the adjacent Indian state of West Bengal have probably involved more than 250 people with a fatality rate of about 70% (49, 57, 68) . The latest outbreak of nine cases in Bangladesh was reported in early 2015 (98) , and a henipavirus outbreak involving 17 people, more likely due to NiV, occurred in the Philippines in 2014 (14).

The natural host of henipaviruses has been confirmed to be bats. HeV has been isolated from Pteropus alecto and a few other Pteropus species (flying foxes) found in Australia (111) . NiV was isolated from P. hypomelanus and P. vampyrus (Malaysia), and P. lylei (Cambodia), and NiV RNA recovered from P. giganteus (India), P. vampyrus (Indonesia) and P. lylei (Thailand) (29, 100, 110, 120) . Viral RNAs of African henipaviruses have been detected in various species of non-pteropid bats, including Eidolon helvum (27). Zoonotic henipavirus transmission to humans can occur in several ways: (i) direct bat-to-human transmission; (ii) bat-to-intermediate host-to-human transmission; and (iii) humanto-human transmission. The best example of bat-to-human transmission was from Bangladesh where humans became infected when they drank raw date palm sap contaminated by NiV-infected bats that had fed at overnight collection pots (67) .

For both NiV and HeV, involvement of intermediate hosts is common. Most likely urine and oronasal secretions from infected animals were responsible for passing the infection to humans through direct or possibly airborne exposure (75, 92, 109) . In the NiV outbreak in Malaysia and Singapore, the pig was the main intermediate host, and pig farmers, abattoir workers, pork sellers and army personnel involved with culling of pigs had the highest prevalence of infection (2, 13, 88, 95, 106) . Bat-to-pig transmission could have resulted from pigs consuming half-eaten, contaminated fruits dropped by bats (20). Other domestic animals such as dogs, cows and goats may have the potential to act as intermediate hosts for NiV (18, 76, 133) . Human HeV outbreaks were closely associated with infection in horses and indeed occurred mainly among veterinarians, stable workers and other personnel in close contact with horses. Though rare, the HeV-infected dog may also have the potential to be an intermediate host (97) . Bat-to-horse transmission remains unclear but is likely to be due to environmental contamination from bat urine or other bat-derived materials (31, 127) . Interestingly, in the henipavirus outbreak in the Philippines, the majority of patients were involved with slaughtering infected horses and/or consuming under-cooked horse meat (14).

Human-to-human transmission was firmly established in the NiV outbreaks in Bangladesh and India where a relatively high incidence was reported either in family members or other people in contact with patients, and in health care workers (44, 49, 54) . Although human-to-human transmission may well have occurred in the Malaysia/Singapore outbreaks, the only well-documented case was in a nurse who seroconverted but remained asymptomatic despite brain magnetic resonance imaging (MRI) that showed a few typical lesions of acute encephalitis (115, 117) . In other health staff involved with patient care, serum neutralization tests were found to be negative, possibly because of good clinical prophylactic measures (78) . In the Philippines' henipavirus outbreak, the clinical and epidemiological evidence also suggested human-tohuman transmission (14). To date, bat-to-human or human-tohuman HeV transmission has not been reported (69) . It is perhaps not surprising that human-to-human henipavirus transmission can occur as virus has been detected in various excretions from patients (21, 92).

The incubation period of henipavirus infections ranges from a few days to about 3 weeks. Milder clinical features include fever, nonspecific influenza-like illness, lethargy, myalgia and headache (14, 16, 37, 92, 109) . In general, the more severe clinical features manifest as either an acute encephalitic syndrome or less frequently a pulmonary syndrome. It is also very likely that there is a considerable number of infections that remained asymptomatic but the exact prevalence is unknown.

As there have been only seven known cases of human HeV infection, much less is known about its clinical manifestations compared with NiV infection. Nonetheless, the acute encephalitic syndrome is characterized by drowsiness, confusion, ataxia, ptosis and seizures. One patient had a pulmonary syndrome described as a pneumonitis with chest radiograph findings of diffuse alveolar shadowing (69, 92, 109) . However, at autopsy, this patient's brain also showed features of acute encephalitis that had not been clinically apparent (134) . Two clinical encephalitis cases also had similar abnormal chest radiographs.

Severe NiV infection appears to be more frequently manifested as an acute encephalitic syndrome. In the largest cohort of 90 patients with acute NiV encephalitis admitted to a single hospital, apart from the symptoms seen in milder infections, 53% of patients had reduced consciousness (37) . Clinical signs such as areflexia/hyporeflexia with hypotonia, pinpoint pupils with variable reactivity, tachycardia, hypertension and abnormal doll's eye reflex were more frequently seen in patients with reduced level of consciousness. Segmental myoclonus characterized by focal, rhythmic jerking of the diaphragm and muscles in the limbs, neck and face was present in 30% of patients, and may be unique to acute NiV encephalitis. Other clinical features (eg, meningism, generalized tonic-clonic convulsions, nystagmus and cerebellar signs) were also observed. Similar findings were also found in patient cohorts from Bangladesh and Singapore (53, 61) . In Bangladesh, altered mental status and/or unconsciousness was reported in >70%, severe weakness in 67% and areflexia/hyporeflexia in 65% of cases, consistent with a high prevalence of acute encephalitis. In the Philippines' henipavirus outbreak, 11 of 17 cases (65%) were reported to have acute encephalitis and 1 case had meningitis but no encephalitis (14).

Generally, brain MRI scans were useful for diagnosis of acute henipavirus encephalitis showing multiple, disseminated, small discrete hyperintense lesions mainly in the cerebral cortex, subcortical and deep white matter (65, 69, 92, 107) . In addition to this, acute HeV encephalitis lesions may be larger and more confluent, similar to some acute NiV encephalitis cases in Bangladesh (99) .

Overall, mortality is high in henipavirus infections ranging from about 40% to 70% (49, 53, 69, 88) . In a large cohort of patients who survived, the majority had no or few sequelae (37) . Some patients were reported to have neurological deficits, neuropsychiatric sequelae and gait/movement disorders (83, 108) . Fatal intracerebral hemorrhage is a very rare complication (37) . The most interesting complication is probably relapsing encephalitis which may occur weeks to years after symptomatic henipavirus infection (mild, non-encephalitis illness or acute encephalitis) and even after asymptomatic NiV infection/ seroconversion (85, 108, 114) . So far, there has been only 1 case of relapsing HeV encephalitis and >20 cases of relapsing NiV encephalitis (possibly involving <10% of survivors), one of which occurred 11 years after an asymptomatic infection (1). Clinical and radiological findings suggest that relapsing NiV encephalitis is distinct from acute NiV encephalitis (107, 114) . The brain MRI in relapsing henipavirus encephalitis shows more extensive and confluent hyperintense cortical lesions. Virus could not be cultured from cerebrospinal fluid, naso-tracheal secretions, urine and brain tissue in a series of NiV relapsing encephalitis (114) .

Detection of anti-henipavirus antibodies remains a key to establishing the diagnosis both in animals and humans because the diagnosis may not be suspected initially, and disease manifestations can be rather nonspecific. Enzyme-linked immunosorbent assays (ELISA) that were developed during the initial HeV and NiV outbreaks in Australia and Malaysia, respectively, proved to be very useful as a screening test and were widely applied to diagnose these infections in animals and humans (122) . Subsequently in Bangladesh, the first NiV outbreaks were only suspected after these tests were found to be positive in patients (54) . In human NiV infection, IgM seroconversion from day 4 to day 12 was about 65%-100%, persisting for at least 3 months, while IgG seroconversion by day 25 was 100% and persisted for several years (17, 101). These tests have also been used widely for investigative field studies in bats and other animals (56, 58, 120) . Specific IgM or IgG has also been reported in HeV-infected patients (47, 85, 109) .

Serum neutralization tests, although accepted as the reference standard to confirm henipavirus infection, may not be done in most laboratories because this test involves handling live viruses which requires biosafety level 4 facilities. An innovative pseudotyped vesicular stomatitis virus bearing the NiV F and G proteins has been used to obviate this requirement, and was shown to be more sensitive than conventional serum neutralization tests, and applicable for both HeV and NiV infections (14, 59, 113) . Specific and reliable PCR-based methods and sequencing (30, 42, 122) to identify henipaviruses are now more widely available for outbreak investigations and diagnosis, and have begun to replace serological testing (51, 111, 140) . Where infected animal or human tissues are available, immunohistochemistry using specific anti-henipavirus antibodies is useful to confirm the diagnosis (34, 130, 133) .

The pathology of acute HeV and NiV infections appears to be similar although our current knowledge of acute henipavirus infection is based on only 3 autopsies of HeV infection, and >30 autopsies of NiV infection (69, 134, 136) . Acute henipavirus infection is characterized by disseminated small vessel vasculopathy comprising endothelial infection/ulceration, vasculitis (Figure 2A ,G) and vasculitis-induced thrombosis/occlusion (Figure 2A) , often resulting in parenchymal ischemia and microinfarction in the central nervous system (CNS) ( Figure 2D) , lung, kidney and other major organs (134, 136) . In about 25% of NiV infections, endothelial multinucleated syncytia have been detected ( Figure 2B ). This feature is probably unique to henipavirus infection as it has not been described in other infections, including measles. Viral antigens/RNA and nucleocapsids were detectable in vascular endothelium, multinucleated giant cells and smooth muscle.

Vasculopathy was most severe in the CNS and frequently associated with discrete necrotic or more subtle vacuolar, plaque-like lesions ( Figure 2D,F) . As neuronal viral inclusions/antigens/RNA were often demonstrable ( Figure 2C ,E,F,H,I), the lesions were probably the result of microinfarction and/or neuronal infection. Similar white matter necrotic lesions were probably pure microinfarcts as glial cells were far less susceptible to infection. Focal neuronophagia, microglial nodule formation, clusters of foamy macrophages, perivascular cuffing and meningitis can also be found but extravascular paramyxoviral Warthin-Finkeldey multinucleated giant cells were absent. The dual pathogenic mechanisms of vasculopathy and parenchymal cell infection in multiple organs may be unique to acute henipavirus infection (136) .

The pathological features of relapsing henipavirus encephalitis were based on an autopsy case of HeV (134) and autopsies of relapsing NiV encephalitis (114, 136) . Relapsing HeV and NiV encephalitides are similar where pathology was confined to the CNS. Confluent and extensive parenchymal necrosis, edema and inflammation were seen mainly in neuronal areas where there was prominent perivascular cuffing, severe neuronal loss, reactive gliosis and neovascularization. Focal viral inclusions/antigens/ RNA and nucleocapsids were demonstrated mainly in surviving neurons. Severe meningitis was found in many areas. Notably, vasculitis, endothelial syncytia and thrombosis seen in acute henipavirus encephalitis were absent and blood vessels were all negative for antigens/RNA. The presence of viral inclusions, nucleocapsids, antigens and RNA confirmed relapsing henipavirus encephalitis as a recurrent infection rather than postinfectious encephalitis (114) . The absence of vasculopathy and extra-CNS organ involvement suggests reactivation of latent viral foci within the CNS rather than virus reentry from an extra-CNS site.

The risk factors for relapsing henipavirus encephalitis are unknown. Clinically and pathologically, relapsing henipavirus encephalitis appears to share some similarities with subacute sclerosing panencephalitis (SSPE). Moreover, like relapsing henipavirus encephalitis, SSPE is not invariably fatal and recurrences have been reported (17, 26, 114 ). Similar measles virus mutations associated with SSPE (11) have so far not been reported in relapsing NiV encephalitis (131) . Measles virus is known to cause immune suppression (39) , and being paramyxoviruses, henipaviruses could possibly cause immune suppression leading to relapsing encephalitis.

Animal studies have contributed to our understanding of henipavirus pathology and pathogenesis (23, 34, 75, 126, 133) . Many mammalian species can be infected either under natural or experimental conditions. The range of susceptible includes the definitive host (bat), known intermediate hosts (horse, pig, dog) and other experimental animal models (mouse, hamster, cat, guinea pig, ferret, chicken embryo, African green monkey and squirrel monkey) (7, 33, 43, 52, 63, 70, 73, 74, 104, 119, 127, 128, 132) . Overall, the findings in animals have confirmed the findings in human autopsies that the acute infection is a disseminated, multi-organ disease characterized by vasculopathy and parenchymal cell infection. This extensive dual pathogenic mechanism of tissue injury is responsible for the severity and high mortality of henipavirus infection.

The bat as the definitive and reservoir host for henipaviruses demonstrated little evidence of pathology except for focal mild vasculitis (126) . Perhaps the hamster and the African green monkey may be the best known animal models for both NiV and HeV because the pathological findings appear to most accurately recapitulate changes in humans, in particular CNS vasculopathy and neuronal infection. Although vasculopathy was invariably present, neuronal infection and encephalitis were not prominent in the ferret, pig, cat, horse and guinea pig (except in high HeV doses) models. NiV infection in mice was subclinical (28), but older mice were susceptible to HeV for reasons possibly related to interferon I response after viral entry (25) or perhaps to other host responses such as CXCL10, a chemokine induced by NiV (72) . An interesting but rare finding was neuronal syncytia formation in the hamster and chicken embryo CNS (118, 133) . In addition to vasculopathy and lung parenchyma infection seen in most animal models, the pig also showed prominent infection and syncytia formation in the bronchial epithelium (63, 133) . The dog has not been studied as model for henipavirus infection but naturally infected animals have some similarity to human pathology (52, 133) .

Apart from the obvious hematogenous spread into the CNS via damaged blood vessel/blood-brain barrier, recent animal studies in pig, mouse and hamster models have demonstrated neuroinvasion via infected nasal mucosa, and then into the olfactory bulb to enter the CNS (28, 80, 124) . So far, there has been no direct evidence for this in human infection (136) . Despite NiV strains from Bangladesh and Malaysia sharing about 91.8% genomic sequence homology (48) , the infectious disease pathology may still differ. To address this question, two separate studies using the hamster model were performed. In one study, the Malaysian strain caused a more accelerated infection (24), but in another study there were no apparent significant differences (3). A study in ferrets also showed no pathological differences except for higher viral titers in oral secretions following infection with the Malaysian strain (22). Further studies by manipulating NiV genome using a recently described infectious clone may be helpful to further understand the differences, if any, between Bangladesh and Malaysian strains (142) . The only study so far that directly compared HeV and NiV infections in an animal model (hamster) did not appear to demonstrate significant differences in the two viruses either, except for the finding that NiV initially replicated in the upper respiratory tract epithelium, whereas early HeV replication was in lung interstitium (105) .

To date, there are no approved vaccines or therapeutic agents to treat human henipavirus infection. Various approaches being pursued as part of ongoing research have been reviewed (8). During the NiV outbreak in Malaysia, ribavirin (a broad spectrum antiviral drug) was given empirically, and subsequently thought to be useful for patients (15). However, its effect on human HeV infections, if any, was uncertain (69) . Nonetheless, as it was found to have some effect on henipaviruses experimentally (36, 139) , ribavirin was further tested for its anti-henipavirus properties either alone or in combination with a potentially useful antimalarial drug called chloroquine (94) . Unfortunately, in the hamster, ferret and African green monkey models, ribavirin or ribavirin/ chloroquine combinations were found to be ineffective against infection and disease (32, 86, 104) . Other drugs have been suggested as having possible anti-henipavirus effects (69) .

Passive immunization strategies using cross reacting, henipavirus-specific antibodies raised against F and G viral proteins have been investigated in hamster, ferret and African green monkey models and found to be effective (5, 7, 35, 40, 41, 43) . In fact, on humanitarian grounds, two patients with HeV infection have been given these antibodies with no adverse effects but the antiviral effectiveness has not been verified (9). Many new vaccine candidates for active immunization using different live recombinant vaccine, subunit vaccine and virus-like particle platforms that mainly express henipavirus F and/or G proteins have been successfully developed and tested in various animal models including hamsters, pigs, cats, ferrets and African green monkeys models (6, 40, 60, 66, 77, 79, 87, 93, 96, 121, 125, 141) . One of the recombinant subunit vaccines that contained the HeV G glycoprotein has now been licensed for use by the equine industry in Australia (103).

As far as newly emerging viruses, including henipaviruses, Ebola virus, SARS coronavirus, are concerned, one of the most important natural hosts is the bat (10, 112, 138) . Because of the (20, 29, 45, 46, 50, 54, 62, 64, 84, 102, 120) . Hence, future henipavirus outbreaks in new areas/countries are probably inevitable as shown by the recent outbreak in the Philippines (14). A group of Africans who were involved with butchering bats for bush meat was recently found to be seropositive, thus providing evidence of previously unknown henipavirus spillover events in a continent that has yet to witness a henipavirus outbreak (90) . The concept of One Health that integrates activities and contributions of international scientists, ecologists, veterinarians, health professionals, politicians and other stakeholders may be needed to minimize future outbreaks of bat-borne zoonoses (112) . 

Henipavirus susceptibility to environmental variables

Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection

Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection

Animal challenge models of henipavirus infection and pathogenesis

Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody

Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah infection

Clinical features of Nipah virus encephalitis among pig farmers in Malaysia

Elucidation of Nipah virus morphogenesis and replication using ultrastructural and molecular approaches

Measles virus. In: Field's Virology

Nipah virus: vaccination and passive protection studies in a hamster model

Antibody prophylaxis and therapy against Nipah virus infection in hamsters

Specific detection of Nipah virus using real-time RT-PCR (TaqMan)

Acute Hendra virus infection: analysis of the pathogenesis and passive antibody protection in the hamster model

Person-to-person transmission of Nipah virus in a Bangladeshi community

Newly discovered viruses of flying foxes

Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus

Hendra virus infection in a veterinarian

Genetic characterization of Nipah virus

Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001

Evidence of Henipavirus infection in West African fruit bats

Hendra virus: what do we know?

Comparative pathology of the diseases caused by Hendra and Nipah viruses

Clinical presentation of Nipah virus infection in Bangladesh

Nipah virus encephalitis emergence

Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals

Henipavirus and Tioman virus antibodies in pteropodid bats

Institute of Epidemiology Disease Control and Research Nipah Virus Outbreak

Nipah virus infection in bats (Order Chiroptera) in Peninsular Malaysia

Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase

Rhadovirus-based vaccine platforms against henipaviruses

The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus

Henipavirus and Tioman virus antibodies in pteropodid bats

Experimental inoculation study indicates swine as a potential host for Hendra virus

Antibodies to Nipah or Nipah-like viruses in bats

Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease

Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters

Transmission of human infection with Nipah virus

Recurrent zoonotic transmission of Nipah virus into humans

Hendra virus: an emerging paramyxovirus in Australia

Primate model for the emergent Nipah virus infection

Cedar virus: a novel henipavirus isolated from Australian bats

Lethal Nipah virus infection induces rapid overexpression of CXCL10

Experimental Nipah virus infection in pigs and cats

Experimental Nipah virus infection in pteropid bats (Pteropus poliocephalus)

Henipavirus in thier natural animal hosts

Nipah virus infection in dogs

Single injection recombinant vesicular stomatitis virus vaccines protest ferrets against lethal Nipah virus disease

A cohort study of health care workers to assess nosocomial transmissibility of Nipah virus

Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine

Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route

A morbillivirus that caused fatal disease in horses and humans

Ephrin B2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus

Neuropsychiatric sequelae of Nipah virus encephalitis

Antibodies to Nipah-like virus in bats

Fatal encephalitis due to novel paramyxovirus transmitted from horses

Chloroquine adminstration does not prevent Nipah virus infection and disease in ferrets

A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge

Case-control study of risk factors for human infection with the new zoonotic paramyxovirus, Nipah virus, during a 1998-1999 outbreak of severe encephalitis in Malaysia

Outbreak of Nipah-virus infection among abattoir workers in Singapore

Evidence of henipavirus spillover into human populations in Africa

Henipavirus receptor usage and tropism

Human Hendra virus encephalitis associated with equine outbreak

Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines

Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy

Assessment of Nipah virus transmission among pork sellers in Seremban

Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease

Hendra virus, equine-Australia (09): (NS) dog affected. Archive number

Nipah encephalitis, human-Bangladesh (02). Archived number

A report of 4 patients with Nipah encephalitis from Rajbari district

Characterization of Nipah virus from naturally infected Pteropus vampyrus bats

Kinetics of IgM and IgG seroconversion in Nipah virus infection

Nipah virus in Lyle's flying foxes

The Hendra vaccine has arrived

A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of Ribavirin treatment

Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection

Nipah virus infection among abbatoir workers in Malaysia

Magnetic resonance imaging features of Nipah encephalitis

Long term neurological and functional outcome in Nipah virus infection

Infection of humans and horses by a newly described morbillivirus

Nipah virus in the fruit bat pteropus vampyrus in Sumatera

Identifying Hendra virus diversity in pteropid bats

Bats and their virome: an important source of emerging viruses capable of infection humans

Development of a neutralization assay for Nipah virus using pseudotype particles

Relapsed and late-onset Nipah encephalitis

Nosocomial transmissibility of Nipah virus

Nipah encephalitis outbreak in Malaysia

Patients with asymptomatic Nipah virus infection may have abnormal cerebral MR imaging

Distribution of viral antigens and development of lesions in chicken embryos inoculated with Nipah virus

Histopathologic and immunohistochemical characterization of Nipah virus infection in the guinea pig

Vaccine potential of Nipah virus-like particles

Diagnosis of henipavirus infection: current capabilities and future directions

Molecular biology of Hendra and Nipah viruses

Invasion of the central nervous system in a porcine host by Nipah virus

Recombinant Nipah virus vaccines protect pigs against challenge

Animal models of henipavirus infection: a review

Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats

Experimental Hendra virus infection in pregnant guinea-pigs and fruit bats

Emerging and re-emerging epidemic encephalitis: a tale of two viruses

Emerging epidemic viral encephalitides with a special focus on henipaviruses

Nipah and Hendra viruses: recent advances in pathogenesis

A golden hamster model for human acute Nipah virus infection

Pathology of acute henipavirus infection in humans and animals

Human Hendra virus infection causes acute and relapsing encephalitis

Nipah virus infection, an emerging paramyxoviral zoonosis

Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis

Clinical and pathological manifestations of human henipavirus infection

Bats as continuing source of emerging infections in humans

RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription

Novel henipa-like virus, Mojiang paramyxovirus, in rats

Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge

Establishment of a Nipah virus rescue system